Attendee search 

Northern Biotechnologies has raised $1.5M in round "a" private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, anti- viral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners.

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti-microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention

can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and anti- viral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets.

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of "green probiotic" cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies. 

Eniluracil/5-FU/leucovorin has promise to produce therapeutic advantages over iv 5 FU and capecitabine

Eniluracil inactivates dihydropyrimidine dehydrogenase (DPD), thereby preventing the formation of α fluoro-β-alanine (F-BAL), and conferring 100% oral bioavailability and a 5 hr half life on 5 fluorouracil (5 FU).  An open-label Eniluracil, 5-FU and leucovorin vs. capecitabine (4:3 randomization) Phase II trial for metastatic breast cancer is in progress. Study drugs are administered orally for 1st- or 2nd-line treatment for metastatic disease in patients previously treated with an anthracycline and a taxane. Arm 1: eniluracil/5-FU/leucovorin administered once/week for 3 weeks/4 weeks. Arm 2: capecitabine (1000 mg/m2) taken bid for 14 days/21days.  Arm 2 patients with disease progression could crossover to take eniluracil/5-FU/leucovorin in Arm X.  Eniluracil/5-FU/leucovorin has been active and well tolerated in both Arm 1 and Arm X.  The primary endpoint, progression-free survival, will be determined approximately 7.5 months after the trial is enrolled with 140 evaluable patients, expected in 2Q 2013.    

Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent organ failure. Xiber will enter market by two niche indications: Acute Lung Injury & Primary Graft Dysfunction after Lung Transplantation – with a total market volume of 630 Mio. USD.
In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start in the beginning of 2016.
Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders. The University holds a non-controlling interest and rewards its shares by providing cooperation, infrastructure, facility services and management support.
To drive its developmental program till the completion of a phase I trial Xiber needs ~ 4 Mio €. This is largely covered by Austrian funds and loans. For the remaining  Xiber seeks 2 Mio € equity from VC partner. Xiber has already signed a LOI with an established VC company. 

Corporate

• Ceronco Biosciences is developing new drugs to fight cancer based on the short-chain sphingolipid (SCS) technology discovered in a collaborative research project at the Netherlands Cancer Institute (NKI) and Erasmus MC.
• Proof of principle has been established in combining the SCS-technology with doxorubicin in highly relevant animal models. Addition of the SCS leads to increase in uptake of doxorubicin, specifically in cancer cells, and subsequently a significant reduction in tumor growth and increase in overall survival. At the same time no increase in severity of expected side effects or new side effects were noted.
• Ceronco is now taking this first product (CB001) into clinical trials, with expected start of the first clinical trial early 2013.

Technology

• A major barrier for uptake of chemotherapeutic drugs is the cellular membrane of a cancer cell. A new class of short-chain sphingolipids (SCS) has been identified which insert themselves into the cellular membrane and lead to catalysis of drug-membrane translocation. This results in increased uptake of a large variety of amphiphilic chemotherapeutic drugs.
• Tumor Cell Membrane Modulation using the SCS-technology is a novel and unique method to increase the efficacy of chemotherpaeutic drugs.

Products

• CB001: GluCer-enhanced liposomal doxorubicin
• CB002: SCS-enhanced mitoxantrone

DIGNA Biotech is a private biotechnology company headquartered in Pamplona (Spain), with offices in Madrid and Pennsylvania (USA). It was founded in 2004 as a spin-off of the University of Navarra. The firm currently has a pipeline of 9 products at different stages of development in 3 therapeutic areas: Inflammatory/Autoimmune, Cardiovascular and Liver diseases.

 Digna Biotech is seeking private funding to spin out a new biotech company to conduct Phase IIb and Phase III trials of its more advanced candidate, a cytokine inhibitor for the treatment of patients with Systemic Sclerosis and Localized Scleroderma. The product (Disitertide) has already completed Phase I, Phase IIa and open-label extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. Orphan drug designation by both FDA and EMA has been granted in the two indications.

InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs.

InteRNA well equipped to move quickly towards the clinic

InteRNA's drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis.

InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available.

With the Company's proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, PAR-CLIP, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their biomarkers quickly towards the clinic.